Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015 Legislation ... includes a pharmacy provision to help prevent inappropriate prescriptions ... The Protecting the Integrity of Medicare Act (PIMA) ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... the prescription drug abuse epidemic and implement the right ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015 The market for IVD ... is estimated at 2.4 billion in 2014.   The ... government insurance, newly insured patients and updated healthcare ... will continue to propel demand.  The healthcare market research ... market and interviews with IVD manufacturers and distributors.  ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4
... MedAxiom, a subscription-based service provider and information resource ... today announced a significant expansion to its Corporate Partner ... Anodyne Health, have joined the program so far this ... cardiology practice members.  MedAxiom now has more than 30 ...
... 27, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Anodyne Health, Seven Other Companies Join in Significant Expansion of MedAxiom Corporate Partner Program 2Anodyne Health, Seven Other Companies Join in Significant Expansion of MedAxiom Corporate Partner Program 3Anodyne Health, Seven Other Companies Join in Significant Expansion of MedAxiom Corporate Partner Program 4Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 2Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 3Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 4Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 5Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 6Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene 7
(Date:2/27/2015)... 27, 2015 Many mattresses contain ... health. Mercola.com has introduced organic cotton mattresses and ... flame retardant chemicals. Dr. Mercola’s Healthy Home mattresses ... better materials. Organic cotton is significantly less flammable ... bedding products are made by Naturepedic and are ...
(Date:2/27/2015)... ResearchMoz has announced the addition ... of the cell culture protein surface coating market ... current scenario and development prospects of the global ... period of 2015 to 2019. , Read Complete ... The research report, titled Global Cell Culture Protein ...
(Date:2/27/2015)... Summit County, CO (PRWEB) February 27, 2015 ... Kevin and Amy Smits help to restore ... year for the last six years, this husband/wife Realtor team ... of the charities have remained the same while others have ... Victims of Assault provides a safe haven and counseling ...
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... 2015 Jvion announced today that ... with the Atlanta-based software company through a strategic ... advanced predictive capabilities suite within the provider market. ... and prevents financial and clinical losses within hospitals. ... help prevent patient deterioration and suffering, the support ...
Breaking Medicine News(10 mins):Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3Health News:Mr. And Mrs. Smits Proves That Altruism Works All Year Round 2Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3
... young children with bottles of fruit juice and sugary drinks, ... Australia. ,Many children turn up requiring as many as ... ,In the most severe cases, pediatric dentists are being left ... ,"It's a tragedy when we see this, but it's ...
... ago there was a theory doing the rounds that the ... individual. This theory was not well received and was ... the proponents of the theory to associate the schemingly silent ... ,Autism is a developmental disability that affects the ...
... is finally on the way for 70-year-old Hakimuddin of ... district administration promising assistance after the impoverished man ... lives. ,The district collector of Bhadrak in ... to conduct an inquiry on the condition of the ...
... is linked to a substantial increase in risk for heart ... findings are published today in the online edition of Science, ... journal. ,Researchers found individuals with the variation have ... infarction) and a 2.02-fold greater risk of suffering a heart ...
... a liver transplant is highly accurate in showing vascular ... recent study. ,The study consisted of 39 ... developing fluid in the abdomen and/or unclear liver function ... in the early post transplant period, caused by acute ...
... to know what makes certain babies prone to SIDS ... the Royal Hospital for Sick Children in Glasgow have closed ... babies which expose them to risks of cot death. ... and child health sciences division, are team leaders of a ...
Cached Medicine News:Health News:Experts Call for Warning Lables on Fruit Juice to Save Kids' Teeth 2Health News:Diet for Autism 2Health News:Diet for Autism 3Health News:Disabled Orissa Brothers Lives Saved by Timely Intervention 2Health News:Genetic Variation is Linked to Substantial Risk in Heart Attack 2
... OEC announced another imaging first with the ... Mobile Imaging System. This breakthrough platform in ... 1K imaging resolution technology available in a ... a new standard for mobile imaging systems ...
... The PS Medical Delta valve is ... fluid (CSF) and maintain intraventricular pressure ... regardless of patient position. The normally ... response to positive ventricular pressure. Working ...
...
... Disposable bars made of silver/silver chloride have ... for easy separation into two individual tabs. ... (page 17). Bar dimensions: 4 cm (1.6 ... Each 200-count package contains 50 individually sealed ...
Medicine Products: